/
Oncology
Carcinoma, Non-Small-Cell Lung
54
Pipeline Programs↗
53
Active Trials↗
32
Companies Involved↗
Carcinoma, Non-Small-Cell Lung is a moderately active landscape with 54 programs across 32 companies. The most active players are Johnson & Johnson, Merck & Co., AstraZeneca. 16 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical7
Phase 15
Phase 226
Phase 316
Approved
No programs
Analysis
Modality Breakdown
73%
Small molecule
36 of 49 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 49 classified programs, each share of the total. Modality classified for 96% of 54 pipeline programs.
Analysis
Trial Status
69
clinical trials
Recruiting22 · 32%
Active, not recruiting22 · 32%
Completed12 · 17%
Not yet recruiting7 · 10%
Terminated4 · 6%
Enrolling by invitation2 · 3%
Clinical Trials
Trial Activity
69 trials
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)